DSRV Articles
Warning-letter analysis, 483 trend reports, and regulatory intelligence for pharma quality teams. Every piece is cited, verified, and written by our Intelligence team.
17 of 48 articles · Enforcement Analysis·Browse by regulation →
August 2026
A Quality Unit That Averaged Away Its Own OOS Failures
FDA's July 2026 warning letter to ABS Corporation shows a Quality Unit that averaged out failing assay results, handwrote higher specification limits onto batch records during validation, and released product made with a raw material that had already failed retesting. The pattern is not sloppy paperwork. It is a Quality Unit deciding the answer before the test ran.
July 2026
FDA Is Treating Discarded Evidence as a Quality Unit Failure
FDA's June 22, 2026 warning letter to Genzyme Ireland shows how undocumented retesting, discarded review artifacts, and canceled deviations now read as quality-unit governance failures. Small pharma quality teams should treat this as a warning that incomplete records are no longer a narrow documentation problem.
June 2026
COAs Are Not Component Verification. Five FDA Warning Letters Just Said So.
Five CGMP warning letters in one posting cycle. Five manufacturers. The common thread: treating a supplier certificate of analysis as the endpoint of component verification instead of one data point in it. FDA's June 2026 cluster makes the distinction explicit.
June 2026
Four Months Under QMSR: Risk Management Is FDA's Top Citation
CDRH's first QMSR inspection data shows NAI falling to 48.8% in the framework's first four months. The top finding is risk management integration. Firms document their risk controls but cannot show they built them. The pattern pharma teams have watched in CAPA citations for years has arrived in the device sector under a new regulatory name.
June 2026
FDA Found Zero Asbestos Testing at Five OTC Manufacturers
On June 2, 2026, FDA issued five coordinated warning letters to OTC drug manufacturers across four countries for the same CGMP failure, without a single on-site inspection. The violation is straightforward. What the enforcement mechanism reveals is not.
June 2026
Eight Warning Letters, One Day: FDA's June 9 Evidence Sweep
FDA posted eight CGMP warning letters in a single June 9 update. Macau-Union and Revlon anchor a multi-domain enforcement case that spans release testing, stability support, and component qualification simultaneously, and the pattern applies well beyond those two firms.
June 10, 2026
The AI Never Told Us: What FDA's First AI Warning Letter Really Means
A Michigan homeopathic drug manufacturer used AI agents to generate SOPs, specifications, and production records. FDA's April 2026 warning letter drew the enforcement line the industry had been watching for.
June 2026
The One FDA Request You Cannot Refuse
Aeroflex's May 2026 warning letter is a rare case. The violation is not a quality failure but a refusal to hand over records. Here is what section 704(a)(4) actually requires, and why no one in your quality team should learn this the hard way.
June 2026
The Certificate of Analysis Is Not a Test
FDA's March 2026 warning letter to Yangzhou H&R Plastic documented three co-occurring failures that define small OTC manufacturer inspection risk: batch release without identity testing, a quality unit with no structural independence, and zero process validation before commercial distribution.
June 2026
FDA Data Integrity Violations Keep Repeating. This Is Why.
FDA has cited data integrity failures under 21 CFR 211.68(b) for years, and recent warning letters against MMC Healthcare and Landy International follow the same pattern. The violation is never really about the data system.
June 2026
Media-Fill Failure Is Not the Root Cause. It Is the Alarm Bell.
FDA’s May 18, 2026 warning letter to Sato Pharmaceutical describes six consecutive media-fill failures as a quality-system credibility collapse. The inspection-readiness lessons span ISO 5/RABS design, smoke studies, contamination prevention, and systemic CAPA, and they generalize far beyond Sato.
May 2026
The CAPAs Were Filed. The Problem Kept Recurring.
Two FDA warning letters from March 2026 cite Medline Industries and Intas Pharmaceuticals not for missing CAPA systems but for CAPA responses that failed to match the size of the problem. The distinction is one most quality teams have not fully internalized.
May 2026
Your Complaint Investigation Is Closed. FDA Says the Risk Is Not.
FDA's January 2026 warning letter to Cohance Lifesciences rejected a re-opened complaint investigation for the same gap it had the first time. The enforcement record documents what happens when a quality unit treats complaint handling and cleaning validation as separate systems.
2026-04-19
DSCSA Enforcement Just Reached Your Medical Spa
FDA's April 1, 2026 warning letter to Pure Indulgence Aesthetics shows the agency applying full DSCSA traceability enforcement to a medical spa that could not prove its Botox came from authorized sources, or prove its inspection response fixed anything.
2026-04-02
Contract Testing Labs Keep Exposing GMP Control Gaps
Two March 2026 FDA-linked signals point to the same problem: contract testing oversight is still being treated as a paperwork exercise instead of a release-critical control. Small quality teams should read these cases as a warning about supplier qualification, data trust, and batch disposition risk.
2026-04-04
What FDA's Data Integrity Remediation Demands Actually Reveal
When FDA's warning letters require independent assessments, patient-risk analyses, and global CAPA strategies, the agency is not just describing consequences. It is disclosing the standards it expected to find before the inspection started.
2026-04-04
Multi-Product API Facilities and the Contamination Gap FDA Finds
FDA's March 2026 warning letter to Henan Lvyuan Pharmaceutical points to a contamination control failure pattern that is structurally embedded in how most multi-product API facilities operate. The gap is not usually in the SOP. It is in the evidence.
